Ticker Details
Prothena Corporation plc Ordinary Shares Prothena Corp PLC is a biotechnology company. It discovers and develops novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion.
IPO Date:	December 21, 2012
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$485.55M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.86 | 2.86%
Avg Daily Range (30 D):	$0.18 | 1.96%
Avg Daily Range (90 D):	$0.22 | 2.26%

Institutional Daily Volume
Avg Daily Volume:	.38M
Avg Daily Volume (30 D):	.37M
Avg Daily Volume (90 D):	.45M

Trade Size
Avg Trade Size (Sh.):	78
Avg Trade Size (Sh.) (30 D):	53
Avg Trade Size (Sh.) (90 D):	58

Institutional Trades
Total Institutional Trades:	3,522
Avg Institutional Trade:	$1.86M
Avg Institutional Trade (30 D):	$.7M
Avg Institutional Trade (90 D):	$1.09M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.17M
Avg Closing Trade (30 D):	$.69M
Avg Closing Trade (90 D):	$1.14M
Avg Closing Volume:	70.44K

News

Nov 12, 2025 @ 2:24 PM Novo Nordisk's $100 Million Coramitug Shows Promis... Source: Vandana Singh

Aug 29, 2025 @ 2:09 PM FDA Tightens Safety Guidelines For Biogen Leqembi ... Source: Vandana Singh

Feb 17, 2025 @ 11:10 PM Kuehn Law Encourages Investors of Prothena Corpora... Source: N/A

Feb 13, 2025 @ 6:00 PM Alpha-Synuclein Inhibitors Clinical Trial Pipeline... Source: Delveinsight

Dec 19, 2024 @ 4:31 PM Roche-Prothena Partnered Mid-Stage Parkinson's Tri... Source: Benzinga

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-5.2	$-.68	$-2.34
Diluted EPS	$-5.2	$-.68	$-2.34
Revenue	$11.79M	$2.42M	$4.42M
Gross Profit
Net Income / Loss	$-280.46M	$-36.54M	$-125.77M
Operating Income / Loss	$-255.33M	$-40.24M	$-84.62M
Cost of Revenue
Net Cash Flow	$-188.42M	$-40.59M	$-46.5M
PE Ratio